A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/21/2012 |
| Start Date: | April 2012 |
| End Date: | November 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of
kidney function in patients with active rheumatoid arthritis (RA).
Inclusion Criteria:
- The patient must meet the American College of Rheumatology (ACR) classification
criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the
seven criteria.
- The patient must have active disease at both Screening and predose on Day 1 of Period
1.
- Patient must have had an inadequate response to at least one disease-modifying
antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or
intolerance.
Exclusion Criteria:
- Pregnant or lactating women
- Serious medical conditions that would make treatment with CP-690,550 potentially
unsafe.
- A patient who has a history of asthma, multiple allergies or severe allergy (eg,
anaphylaxis) to any substance. In particular, a history of allergy to iodine,
povidone-iodine, iohexol or other iodinated contrast media.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials